NCT00003677View on ClinicalTrials.gov

Dolastatin 10 in Treating Patients With Metastatic Pancreatic Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

February 1, 1999

Primary Completion Date

January 16, 2002

Study Completion Date

January 16, 2002

Conditions
Pancreatic Cancer
Interventions
DRUG

Dolastatin 10

IV bolus once every 21 days.

Trial Locations (2)

60637

University of Chicago Cancer Research Center, Chicago

77030

University of Texas - MD Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT00003677 - Dolastatin 10 in Treating Patients With Metastatic Pancreatic Cancer | Biotech Hunter | Biotech Hunter